Critical

Hypereosinophilic syndrome with organ involvement

Eosinophilic · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Persistent marked eosinophilia (typically greater than 1.5 x 10^9/L) causing eosinophil-mediated organ damage - cardiac (endomyocardial fibrosis), neurological, pulmonary, skin or GI - which can be rapidly life-threatening.

Red flags

  • Cardiac involvement (heart failure, thrombus, arrhythmia)
  • Thromboembolism
  • Neurological deficits
  • Very high or rapidly rising eosinophil count

Assessment

Differential diagnosis

  • Eosinophilic granulomatosis with polyangiitis
  • Parasitic infection
  • Drug reaction (DRESS)
  • Eosinophilic leukaemia
  • Lymphoma / secondary eosinophilia

Investigations

  • FBC and blood film (eosinophilia)
  • Troponin, ECG, echocardiography (cardiac involvement)
  • U&E, LFTs
  • Investigations for cause (tryptase, FIP1L1-PDGFRA, parasites, imaging)
  • Bone marrow if primary/clonal disease suspected

Management

  • Assess and support organ function, especially cardiac (a major cause of death)
  • Exclude secondary causes (parasites, drugs, malignancy)
  • Give high-dose corticosteroids promptly for organ-threatening disease (after excluding untreated strongyloides where relevant)
  • Add specific therapy for clonal disease (e.g. imatinib for FIP1L1-PDGFRA-positive disease) on specialist advice
  • Anticoagulate for eosinophilic cardiac thrombus per specialist input
  • Involve haematology/immunology urgently

Drugs & doses

High-dose corticosteroids for organ-threatening disease
Imatinib for FIP1L1-PDGFRA-positive (myeloid) variant
Anticoagulation for cardiac/intracardiac thrombus per specialist
Consider empirical anti-helminthic (e.g. ivermectin) before steroids if strongyloides risk

Disposition

Admit; ICU/cardiology for cardiac involvement; haematology/immunology involvement.

Complications & pitfalls

  • Endomyocardial fibrosis and heart failure
  • Thromboembolic events (including stroke)
  • Respiratory failure
  • Death

Exam pearls

  • Cardiac involvement is the leading cause of morbidity and mortality - image the heart early
  • Exclude and treat strongyloides before giving steroids where there is exposure risk (steroids can precipitate hyperinfection)
  • Identify the FIP1L1-PDGFRA fusion - it responds dramatically to imatinib

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.